Skip to main content

Table 1 Demographic and disease characteristics of psoriasis patients with self-reported PsA in the PSOLAR registry: Overall population

From: Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

 

Ustekinumab (N = 628)

TNF inhibitorsa (N = 1413)

Infliximab (N = 258)

Etanercept (N = 481)

Adalimumab (N = 674)

Non-biologic /MTXb (N = 98)

Non-biologic /non-MTXc (N = 208)

Alld (N = 2401)

Age, years

 Mean ± SD

49.7 ± 12.6

50.4 ± 12.5

49.5 ± 12.6

51.1 ± 13.0

50.4 ± 12.0

55.6 ± 12.3

53.4 ± 14.3

50.8 ± 12.8

Sex

 Men

352 (56.1)

757 (53.6)

138 (53.5)

259 (53.8)

360 (53.4)

34 (34.7)

99 (47.6)

1272 (53.0)

Race

 White

527 (83.9)

1157 (81.9)

223 (86.4)

392 (81.5)

542 (80.4)

80 (81.6)

190 (91.3)

2000 (83.3)

Body mass index (BMI) (kg/m2)

 N

617

1372

245

471

656

93

203

2339

 Mean ± SD

32.1 ± 7.0

31.7 ± 7.4

32.9 ± 8.4

31.1 ± 7.3

31.7 ± 7.1

30.8 ± 7.3

30.6 ± 6.9

31.7 ± 7.2

 Obesity class

  N

617

1372

245

471

656

93

203

2339

 Underweight-normal (BMI < 18.5–24.9)

80 (13.0)

209 (15.2)

29 (11.8)

81 (17.2)

99 (15.1)

24 (25.8)

41 (20.2)

359 (15.3)

 Overweight-obesity class I (25.0–34.9)

353 (57.2)

779 (56.8)

136 (55.5)

268 (56.9)

375 (57.2)

43 (46.2)

110 (54.2)

1315 (56.2)

 Obesity class II-III (35.0- ≥40)

184 (29.8)

384 (28.0)

80 (32.7)

122 (25.9)

182 (27.7)

26 (28.0)

52 (25.6)

665 (28.4)

Psoriasis disease characteristics

 Duration of psoriasis, years

  N

627

1400

256

477

667

97

208

2385

  Mean ± SD

20.8 ± 13.0

19.0 ± 13.4

20.1 ± 13.8

18.0 ± 13.6

19.3 ± 13.2

17.4 ± 13.5

17.5 ± 15.4

19.3 ± 13.6

 BSA involvement (%)

  N

616

1383

247

472

664

96

205

2353

  Median

6.0

4.0

4.0

3.8

4.0

6.0

8.0

5.0

 Baseline PGA score

  N

618

1386

249

474

663

96

205

2359

  Mean ± SD

2.3 ± 1.2

1.9 ± 1.2

1.9 ± 1.2

1.9 ± 1.2

2.0 ± 1.3

2.4 ± 1.1

2.5 ± 1.1

2.1 ± 1.2

Medical historye

  PsA

628 (100.0)

1413 (100.0)

258 (100.0)

481 (100.0)

674 (100.0)

98 (100.0)

208 (100.0)

2401 (100.0)

  Cardiovascular disease

272 (43.3)

605 (42.8)

121 (46.9)

214 (44.5)

270 (40.1)

43 (43.9)

100 (48.1)

1040 (43.3)

  Psychiatric illness

158 (25.2)

344 (24.3)

69 (26.7)

117 (24.3)

158 (23.4)

21 (21.4)

49 (23.6)

584 (24.3)

   Anxiety

84 (13.4)

196 (13.9)

40 (15.5)

69 (14.3)

87 (12.9)

10 (10.2)

31 (14.9)

327 (13.6)

   Depression

116 (18.5)

236 (16.7)

46 (17.8)

78 (16.2)

112 (16.6)

14 (14.3)

36 (17.3)

413 (17.2)

  Inflammatory bowel disease

16 (2.5)

37 (2.6)

8 (3.1)

11 (2.3)

18 (2.7)

4 (4.1)

5 (2.4)

64 (2.7)

   Crohn’s disease

4 (0.6)

9 (0.6)

2 (0.8)

3 (0.6)

4 (0.6)

1 (1.0)

1 (0.5)

16 (0.7)

   Ulcerative colitis

3 (0.5)

10 (0.7)

2 (0.8)

2 (0.4)

6 (0.9)

1 (1.0)

1 (0.5)

15 (0.6)

   Indeterminate colitis

6 (1.0)

15 (1.1)

4 (1.6)

5 (1.0)

6 (0.9)

2 (2.0)

3 (1.4)

26 (1.1)

  Pulmonaryf

94 (15.0)

225 (15.9)

40 (15.5)

76 (15.8)

109 (16.2)

21 (21.4)

46 (22.1)

395 (16.5)

  Hepatic

22 (3.5)

56 (4.0)

14 (5.4)

19 (4.0)

23 (3.4)

2 (2.0)

9 (4.3)

92 (3.8)

  Skin cancer

28 (4.5)

88 (6.2)

14 (5.4)

38 (7.9)

36 (5.3)

6 (6.1)

15 (7.2)

144 (6.0)

  Other cancers

17 (2.7)

48 (3.4)

9 (3.5)

18 (3.7)

21 (3.1)

13 (13.3)

14 (6.7)

95 (4.0)

 Endocrine

135 (21.5)

315 (22.3)

60 (23.3)

113 (23.5)

142 (21.1)

26 (26.5)

52 (25.0)

539 (22.4)

  Diabetes mellitus type I

8 (1.3)

23 (1.6)

6 (2.3)

10 (2.1)

7 (1.0)

1 (1.0)

7 (3.4)

39 (1.6)

  Diabetes mellitus type II

90 (14.3)

181 (12.8)

35 (13.6)

62 (12.9)

84 (12.5)

15 (15.3)

33 (15.9)

325 (13.5)

  Thyroid dysfunction

46 (7.3)

134 (9.5)

25 (9.7)

47 (9.8)

62 (9.2)

13 (13.3)

18 (8.7)

218 (9.1)

  History of infectionsg

167 (26.6)

388 (27.5)

84 (32.6)

137 (28.5)

167 (24.8)

23 (23.5)

43 (20.7)

641 (26.7)

 Social activitye

  Alcohol use, N

628

1413

258

481

674

98

208

2401

   Never used

130 (20.7)

301 (21.3)

70 (27.1)

91 (18.9)

140 (20.8)

47 (48.0)

55 (26.4)

545 (22.7)

   Current user

426 (67.8)

905 (64.0)

161 (62.4)

302 (62.8)

442 (65.6)

35 (35.7)

120 (57.7)

1521 (63.3)

   Have used and stopped

72 (11.5)

207 (14.6)

27 (10.5)

88 (18.3)

92 (13.6)

16 (16.3)

33 (15.9)

335 (14.0)

  Smoking, N

628

1412

257

481

674

98

208

2400

   Never smoked

256 (40.8)

651 (46.1)

122 (47.5)

220 (45.7)

309 (45.8)

47 (48.0)

85 (40.9)

1059 (44.1)

   Current smoker

147 (23.4)

287 (20.3)

61 (23.7)

85 (17.7)

141 (20.9)

24 (24.5)

53 (25.5)

521 (21.7)

   Prior smoker, stopped

225 (35.8)

474 (33.6)

74 (28.8)

176 (36.6)

224 (33.2)

27 (27.6)

70 (33.7)

820 (34.2)

  1. Data are n (%) unless otherwise indicated
  2. The biologic user cohort includes patients who are on the cohort defining biologic at entry or start the biologic after entry; previous use or current exposure is allowed for MTX, but not for other systemic immunomodulators
  3. BMI body mass index; BSA body surface area; MTX methotrexate; PGA Physician’s Global Assessment; PsA psoriatic arthritis; PSOLAR Psoriasis Longitudinal Assessment and Registry; SD standard deviation
  4. aTumor necrosis factor (TNF) inhibitors include infliximab, etanercept, and adalimumab
  5. b The non-biologic/MTX cohort includes patients who are on methotrexate at entry or start methotrexate during the registry and haven’t been exposed to other systemic immunomodulators previously or concurrently
  6. cNon-biologic, non-MTX therapies may include, but are not limited to, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, oral corticosteroids, systemic retinoids, psoralen plus ultraviolet (UV), or UVB phototherapy. The non-biologic/non-MTX cohort includes patients who are on other systemic immunomodulators (including cyclosporine, tacrolimus, mycophenolate mofetil, other immunomodulators, and oral corticosteroids) at entry or start other immunomodulators after registry and who haven’t been exposed to MTX previously or concurrently; patients who are on or receive only topical and/or phototherapy at/after registry entry are also in this cohort
  7. dIncludes “Other biologics” group (n = 54); data not shown
  8. eData were collected at baseline (defined as the last non-missing value that is closest and prior to/on the cohort start date)
  9. fIncludes sleep apnea, asthma, chronic obstructive pulmonary disorder, and pneumonitis
  10. gHistory of infections is defined as infections within 3 years of enrollment and required a prescription medication
  11. Obesity class based upon National Heart Lung and Blood Institute Obesity Education Initiative http://www.nhlbi.nih.gov/health/public/heart/obesity/lose_wt/bmi_dis.html
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us